Byfavo (Remimazolam Besylate) Patent Expiration, LOE Window & CMS Spending

Byfavo (Remimazolam Besylate) by Acacia: FDA Orange Book LOE 2034-01-13, 0 AB generics, $54K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAcacia
FDA Application & PathwayN212295 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2034-01-13
Orange Book Patents (*PED Extensions)11 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$54K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$54K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel